Le Lézard
Classified in: Health
Subject: MAT

Introducing Luxury Dentistry NYC, Dr. D. Signature Face with EVOKE


NEW YORK, July 31, 2020 /PRNewswire/ -- What is Evoke? Evoke is the first and only FDA cleared non-invasive Facial Remodeling treatment that is painless and offers tightening and lifting to deliver more defined facial characteristics with no downtime.

The areas that can be treated are the perfect way to create and maintain a youthful face to frame your smile. 

Evoke consists of two separate treatments; one for the face and the other for the chin.

Each session ranges anywhere from 15-45 minutes with a hands free application that will allow you to relax and watch Netflix or enjoy some music and relaxation. Evoke is a very comfortable treatment that should feel like a warm stone massage.

The results are outstanding and consistent due to Artificial Intelligence that will regulate temperature and sense impedance every millisecond to maintain proper energy for the desired result. No other non-invasive treatment can compete or compare to the comfort, efficacy, and results of Evoke.

Ideal Candidates for Evoke:

Call or text us today to learn more or to schedule an appointment 212.759.7535

Contact:
Dorene Rivera
646-730-4838
http://www.luxurydentistrynyc.com/

SOURCE Luxury Dentistry NYC


These press releases may also interest you

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...



News published on and distributed by: